To confirm whether FLT3 inhibition has a direct effect on AP-1 and RUNX1 binding in chromatin, we performed FOS and RUNX1 ChIP-Seq experiments in FLT3-ITD+ AML cell lines before and after treatment with Gilteritinib (Figure 2G). This evidence concerns the gene JUN and acute myeloid leukemia.